EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Trial · NCT02635386
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Oral Disposition (Insulin Sensitivity-insulin Secretion) Index | 24 weeks of treatment | index score | MEAN | |
| SECONDARY | Absolute Body Weight | 24 weeks of treatment | kilogram | MEAN | |
| SECONDARY | Body Mass Index (BMI) | 24 weeks of treatment | kilogram/meter squared | MEAN | |
| SECONDARY | Change in Percent Body Weight | Change from baseline (time 0) to study end (24 weeks) | percentage change in body weight | MEAN | |
| SECONDARY | Central Adiposity (Waist Circumference) | 24 weeks of treatment | centimeters | MEAN | |
| SECONDARY | Waist-to-Hip Ratio (WHR) | 24 weeks of treatment | ratio | MEAN | |
| SECONDARY | Waist-to-Height Ratio (WHtR) | 24 weeks of treatment | ratio | MEAN | |
| SECONDARY | Total Fat Mass (kg) Evaluated by DEXA | 24 weeks of treatment | kilogram | MEAN | |
| SECONDARY | Total Body Fat (%) by DEXA | 24 weeks of treatment | percent fat mass | MEAN | |
| SECONDARY | Android-Gynoid Ratio (AGR) as Determined by DEXA | 24 weeks of treatment | ratio | MEAN | |
| SECONDARY | Trunk/Leg Fat Ratio by DEXA | 24 weeks of treatment | ratio | MEAN | |
| SECONDARY | Fasting Blood Glucose | 24 weeks of treatment | mg/dL | MEAN | |
| SECONDARY | OGTT Mean Blood Glucose (MBG) | 24 weeks of treatment | mg/dL | MEAN | |
| SECONDARY | Fasting Insulin Sensitivity (HOMA-IR) | 24 weeks of treatment | index score | MEAN | |
| SECONDARY | Matsuda Sensitivity Index Derived From the OGTT(SI OGTT) | 24 weeks of treatment | index score | MEAN | |
| SECONDARY | Corrected First Phase Insulin Secretion (IGI/HOMA-IR) | 24 weeks of treatment | index score | MEAN | |
| SECONDARY | Total Cholesterol Levels | 24 weeks of treatment | mg/dL | MEAN | |
| SECONDARY | Triglyceride (TRG) Levels | 24 weeks of treatment | mg/dL | MEAN | |
| SECONDARY | Total Testosterone Concentrations | 24 weeks of treatment | ng/dL | MEAN | |
| SECONDARY | Dehydroepiandrosterone Sulfate (DHEA-S) Levels | 24 weeks of treatment | mcg/dL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02635386/outcomes